Entities

Clinical research specialist with a PhD in medical microbiology.

Co-founded StackAdapt with Vitaly Pecherskiy and Yang Han.

Computer vision and machine learning researcher with a computer science PhD from Bristol.

Jake Kornreich brings over a decade of leadership in high-growth B2B SaaS to CoLab. Most recently CFO at Own Company (formerly OwnBackup), he helped scale the business to 900+ employees across seven countries, raised several hundred million in capital, and led key operations as the company grew—culminating in a $2.2B acquisition by Salesforce.

Medical device quality and regulatory affairs specialist.

Jeremy Andrews is a mechanical engineer turned technologist who co-founded CoLab after seeing firsthand how slow and fragmented design collaboration can be. While working at Tesla and General Dynamics, he led DFM reviews that could take up to eight weeks on a single part—an experience that sparked his conviction that engineering teams needed a better way to make design decisions.

Jessie Wheeler brings her expertise as a proven scale-up operator to CoLab, having helped lead Own Company to a $2B+ exit before driving strategic initiatives at Salesforce. She joins at a key inflection point, bringing the experience and urgency needed to turn momentum into durable, repeatable scale.

Software engineer and technical architect with medical technology and startup experience.

Software entrepreneur and business angel; founded Media Net Software and co-founded BuyVIP.

Clinical professor at Stanford and director of medical dermatology at Stanford Health Care.

Leads product marketing at StackAdapt.

Marketing executive with experience scaling consumer technology and health technology brands.

Consultant dermatologist at Chelsea and Westminster Hospital working on teledermatology and skin surgery.

MJ Smith brings a mix of manufacturing and SaaS experience to her role as CoLab’s CMO. She started her career as a hardware product manager, working directly with engineering teams across several manufacturing businesses within FTSE 100 Halma plc, where she became the youngest executive director of a Halma operating company at age 24.

Leads customer onboarding, adoption, growth and retention at Blue J.

Product executive at Blue J; previously Chief Product Officer at DocuSign and founder of Yield Software.

Leads advertising technologies at StackAdapt.

Founded Skin Analytics in 2012; previously a GSMA director supporting mobile banking.

Consultant dermatologist with interests in skin cancer and immunosuppressed patients.

Leads StackAdapt’s legal function; promoted from General Counsel in October 2026.

With nearly three decades of experience in cybersecurity, IT, cloud, and software development—including over 15 years in leadership—Robert Percy brings deep expertise to protecting what matters most to CoLab’s customers: their product designs and intellectual property. As CIO, he led the company to achieve and maintain SOC 2 Type 2, ISO 27001, and TISAX AL3 certifications, ensuring the highest standards of security and trust.

Leads people and culture, talent and organizational operations at Blue J.

Chief Marketing Officer at StackAdapt.

Public health physician and rural general practitioner with medical leadership experience.

Leads Blue J go-to-market operations and global commercial expansion.

Sydney Strader brings extensive experience building and leading Customer Success organizations at scaling SaaS companies. Before joining CoLab, she spent three years at InVision, rising from Customer Success Manager to Vice President as the company scaled to $100M in ARR. She then served as SVP of Customer Success at Catalyst Software, leading the team through the company’s successful acquisition.

Taylor Jones brings more than 15 years of experience leading sales and business development teams in high-growth software companies. Before joining CoLab, she held sales and business development leadership roles at Salesforce and helped scale revenue at Zip, a leading intake-to-procure platform, from early growth through the scale-up phase.

Taylor Young has been part of CoLab’s journey from the earliest days, helping shape the company into what it is today. She built CoLab’s business development, marketing, and customer success functions from zero to one and has worked directly with hundreds of engineering teams across industries—from automotive to aerospace and defense.

Leads Blue J go-to-market execution; previously Chief Operating and Customer Officer at Vena Solutions.

Tom Greever is a design leader known for helping teams turn strong design instincts into cohesive, scalable systems. He joined CoLab drawn by its commitment to keeping its engineering platform human-first while integrating the best of what AI has to offer.

Co-founder and CEO of StackAdapt, which develops an AI advertising and marketing platform.

StackAdapt co-founder and CTO; leads technology for its AI advertising platform.

Elisa Nenning is Director Communications & Founder Associate at NexDash. Former Global Communications Director at Grover and ex-Sony Pictures. Leads brand, communications and executive positioning at NexDash.

Gergö Birkas is M&A Origination Lead, DACH at NexDash. 15 years in freight forwarding and fleet advisory with a deep network of carrier owners across DACH. Leads M&A origination at NexDash.

Parth Patne is Lead AI Engineer at NexDash. M.Sc. in AI Engineering. Building NexOS from the ground up. Multiple published research papers on AI.

Berit Inga Stranz is VP Sales & Strategic Partnerships at NexDash. Former VP Business Development & Strategic Partnerships at Grover. Leads shipper relationships and strategic partnerships at NexDash.

Esteban Escalante is VP Operations & Electrification at NexDash. Former CCO at Grover and a key driver of its growth from €10M to €300M ARR. Leads NexDash's electrification and energy transition.

Franck Pascault is Chief Financial Officer at NexDash. Former CFO & Managing Director at Tourlane and ex-Goldman Sachs investment banker. Leads NexDash's finance, capital strategy and M&A.

Karsten Sachsenröder is Chief Operating Officer at NexDash. Former CxO at DB Schenker with 30+ years of experience building and operating transport and logistics businesses. Leads NexDash's carrier operations and integration.

Michael Cassau is Founder & CEO at NexDash. Founder of Grover, scaling the company from zero to $300M ARR and a $1B+ valuation. Now applying the same technology, assets and capital playbook to build Europe's first neo-carrier.

Berlin company developing an integrated, AI-operated electric freight network. NexDash acquires established trucking operators, electrifies their fleets and operates them using NexOS, its proprietary platform for route planning, energy and charging optimization, maintenance and fleet financing. It was founded in 2025 by Michael Cassau and originated from his Platform Horizons investment platform. Autonomous freight is a future development goal; electric fleet operations began in 2026. NexDash announced a EUR5 million seed round in November 2025, led by Extantia Capital with Clean Energy Ventures and Magnetic Capital participating. EIT Urban Mobility announced a EUR2.5 million pre-Series A investment commitment in June 2026; this is recorded separately from completed seed financing.

London-based AI evaluation company founded by Lucas Theis in 2024. Mabyduck provides a self-service platform for measuring human perceptions of AI-generated images, audio, video and interactive experiences. It supports configurable pairwise comparisons, standardized audio tests, surveys, rater screening, custom rubrics, leaderboards and API-driven evaluation workflows. Its public beta launched in November 2025. The company disclosed a pre-seed financing led by Zero Prime Ventures with participation from Berlin-based Magnetic Capital; the amount and closing date were undisclosed. Named supporters include AI researchers described collectively as angel investors and advisers, without individual investment terms.

Ivan Gerov is identified as a Software Engineer by Mabyduck in its January 2026 interactive-avatar evaluation publication. His professional profile confirms Mabyduck and an Aston University background including cognitive psychology and an EEG-based visual-attention study. An authentic portrait was not recovered from accessible primary sources.

Lucas Theis founded Mabyduck, a human-feedback evaluation platform for generative AI. He previously researched neural compression at Google Brain and DeepMind and worked at Twitter following its acquisition of Magic Pony Technology. His PhD at the University of Tübingen and Max Planck Research School focused on probabilistic generative image models. Companies House identifies him as Lucas Marvin Theis, director since July 2024.

Till Aczél is a Research Scientist at Mabyduck, working on perceptual quality assessment of AI-generated images. His own website records a research internship beginning January 2026 and a full-time research-scientist appointment on July 1, 2026. He also researches neural compression and efficient deep learning as a PhD researcher at ETH Zurich with Roger Wattenhofer.

William Blackie is Staff Engineer at Mabyduck, building full-stack products with Python and TypeScript. His personal website lists the role from April 2025 onward and earlier work at Torchbox, Developerfy and a Google DeepMind contract. He maintains the Mabyduck-supported django-vrt visual-regression project.

Zihao Qi co-authored Mabyduck’s January 2026 evaluation of interactive AI avatars, with the company identifying the role as Research Intern. The appointment dates and continued status after that publication are undisclosed. This record concerns the Mabyduck evaluation researcher and is distinct from researchers with the same name in physics, mass spectrometry and electrical engineering.

Christoph Wintersteiger is a senior computer scientist at Imandra. His research covers software verification, decision procedures and automated reasoning, following doctoral work at ETH Zurich.

Makar Valentinov works in research and engineering at Imandra. His company biography describes a Cambridge physics background and interests in computational physics, neural networks and financial technology.

Brian Schwieger is an Imandra strategic advisor with experience in financial-market leadership and governance. He previously led equity trading at LSEG and held roles at Bank of America Merrill Lynch and Morgan Stanley.

Cruise Song is listed as an Imandra research intern. His work connects automated reasoning and interactive theorem proving, including Lean, with a research affiliation at Georgia Institute of Technology.

Stephanie Radics manages operations at Imandra, covering team logistics, finance and employee relations. Her earlier operations work was in hospitality and property management.

Sebastian P is listed as a principal engineer at Imandra, with experience in cloud development and typed functional languages. His published company profile identifies him by a surname initial rather than a full surname.

Eric Meinhardt works in research and engineering at Imandra. His interests include typed functional programming, domain-specific languages, automata and reasoning about state machines; he holds a linguistics PhD.

Hongyu Lin works in research and engineering at Imandra, focusing on machine learning for financial time series. He studied financial mathematics at Central University of Finance and Economics and the University of Leeds.

Kostya Kanishev, also identified as Konstantin in his company biography, works in AI research and engineering at Imandra. His background combines particle-physics research, work at CERN and computer science.

Elijah Kagan is Imandra's head of design. His experience spans agency and independent design, creative development and work for global businesses and institutions.

Andrey Ignatovich works in senior research and engineering at Imandra. His background includes enterprise software development at ADP/CDK and computer-science and astronomy studies at Saint Petersburg State University.

Bence Graics works in Imandra research and engineering, applying formal methods to model-based systems engineering and SysML v2. He developed the Gamma Statechart Composition Framework and earned a PhD in Budapest.

Paul Brennan is chief strategy officer at Imandra. His background includes product and strategy in financial markets and serving as COO of Goldman Sachs' regulated trading venue. He is distinct from the Curve Therapeutics scientific advisor with the same name.

Remi Desmartin is listed as a research fellow at Imandra. His research focuses on neural-network verification, including work applying Imandra to that problem at Heriot-Watt University.

Samer Abdallah works in research and engineering at Imandra. His background spans music informatics, Bayesian modelling, functional and logic programming, with research experience at King's College London and Queen Mary University of London.

Zehra Akbar is Imandra's chief operating officer. She previously helped establish Boeing and SparkCognition's SkyGrid joint venture and led its strategy function, following roles at SparkCognition, Deloitte and Accenture.

Grant Passmore is Imandra's co-founder and co-CEO, leading its automated reasoning technology. His research covers formal verification, symbolic AI and nonlinear theorem proving. He earned a PhD at Edinburgh.

Denis Ignatovich co-founded Imandra and serves as co-CEO. He previously led Deutsche Bank London's central risk trading desk and brings experience in quantitative finance and trading-system design.

Austin and London AI company developing cloud-scale automated reasoning and formal verification for critical software. Its ImandraX reasoning engine, CodeLogician and connectivity tools combine symbolic logic with generative AI to analyse program behaviour, prove properties and expose edge cases. Applications include financial-market infrastructure, AI-generated code, government, defence and autonomous systems. Co-founded by Denis Ignatovich and Grant Passmore, Imandra announced a $5 million seed financing in April 2019 co-led by AlbionVC, IQ Capital and LiveOak Venture Partners. Neurosymbolic AI describes its computing approach; this is not a neuroscience drug or brain-interface company.

Robert Quick is co-founder and COO of trawa, responsible for operations and finance at its AI-enabled energy supplier.

Max Lüddemann is co-founder and CTO of trawa, responsible for software development and data analysis for its AI-enabled energy platform.

David Budde is co-founder and CEO of trawa, responsible for product development, sales and partnerships at the Berlin AI-enabled energy supplier.

Luma Group is a New York investment firm backing biotechnology companies from early discovery through clinical development and commercialization. It combines biological research and computational analysis to evaluate therapies, diagnostics and medical devices, and supports portfolio companies with scientific and operational expertise. Its LABI AI system helps analyze research data and assess scientific breakthroughs. LumaBio Fund I closed at $410 million in September 2026 and has a 15-year investment structure.

Jamie Kasuboski serves on Character Biosciences’ board; the company lists their affiliation as Luma Group.

Luma Group co-founder and partner with a scientific research background in genomics, neuroscience and cancer biology; serves on the Aeovian Pharmaceuticals board.

David Rosskamp is the founding partner of Magnetic Capital, a European venture capital firm investing in technology for critical industries. He is identified as its Managing Partner in the 2024 STARTUPLAND speaker directory and as Founding Partner in NaroIQ’s June 2025 financing announcement. His work covers infrastructure, security, financial technology and industrial technology.

Adrian is a Director of Research in machine learning at the University of Cambridge and Head of Safe and Ethical AI at the Alan Turing Institute.

Ajay Agrawal is the Geoffrey Taber Chair in Entrepreneurship and Innovation and Professor of Strategic Management at the University of Toronto’s Rotman School of Management.

Tap is a seasoned leader with 25+ years of experience leading strategy, technology, business and corporate development at worldwide technology companies ranging from start ups to Fortune 100. He is passionate about developing and leading cross-functional teams to achieve bold goals on a global scale.

AI and genomics executive who previously led Genomics England and served as COO of QuantumBlack. At PhysicsX, he leads commercial expansion and operational scale.

Technology executive and former Databricks EMEA CTO, leading PhysicsX technology and platform development.

Emily is an Internal Operations Lead, supporting the leadership team and office operations in the UK. Prior to joining Intrepid, she served as Executive Assistant to the Chief Executive Officer and senior leadership team at Opto Investments in New York. Earlier in her career, Emily was an Executive Assistant to the President and Chief Executive Officer at CPP Investments in Toronto.Emily holds a Bachelor of Commerce from Royal Roads University.

George Hoyem is a distinguished venture capital executive and technology leader with over 25 years of experience spanning venture capital, entrepreneurship, and the national security intelligence sector. As Executive Vice President of Investments at In-Q-Tel (IQT)—the strategic venture capital arm of the CIA and U.S. Intelligence Community—George led a team that invested in more than 800 dual-use and defense-first startups. His focus areas included advanced analytics, AI, cloud, cybersecurity, and IT infrastructure, ensuring that critical emerging technologies reached national security agencies.

Graham leads the productization of Intrepid's investment process, including the development of our internal AI platform.

Grant helps lead our North America investing efforts and covers our investments in Beacon, CoLab, StackAdapt, and Blue J. Prior to Intrepid, Grant was an Associate at OMERS Growth Equity where he was part of the founding team and supported several direct investments in late-stage software and technology companies across Canada and the United States. He began his career as a Consultant at Monitor Deloitte where he advised clients on corporate strategy and operations with a focus on financial services.

Jess supports our sourcing and investing efforts in North America. Prior to Intrepid, Jess was a Senior Associate at General Atlantic in New York, where she executed growth and buyout investments and supported portfolio companies across the healthcare services industry, with a focus on value-based care, hospital partnership models, and behavioral health. Prior to GA, Jess was an Investment Banking Analyst at J.P. Morgan in New York, where she worked in the Healthcare group.

Jess is a senior associate on the investment team in Europe. Prior to Intrepid, Jess worked as an investor at ex/ante, investing across cybersecurity, AI, web3, and data infrastructure. She previously worked with CrossBoundary in Lebanon, Iraq, and Afghanistan as an investment advisor, where she worked on deals spanning tech, telco, and manufacturing. Jess also worked at Bain London, mostly within the PE due diligence ringfence, and with the UK Foreign Office, where she worked with the counter-ISIS taskforce in 2015.

John is a seasoned AI and Data Science leader with experience as an Operator, Investor and Research Scientist.

Strategy and Programs Manager at PhysicsX, as listed in the company team directory.

Mark trained in Physiological Sciences including specialization in neurosciences at Oxford, researched developmental biology, and studied Clinical Medicine at Cambridge before pursuing a career in finance. For more than two decades he worked at Goldman Sachs in Europe and Asia where he was a Partner and among other roles was Vice Chair and the Head of Investment Banking for Asia Pacific. He then joined CPPIB first as Head of International and then served as President and CEO for five years. Under his leadership, CPPIB grew its exposure to technology investing by launching a Venture and Growth Equity strategy, opening an office in San Francisco, and creating partnerships with leading venture firms and incubators, like the Creative Destruction Lab.

My interest in technology began in the early 1980s when my brother and I received a TRS-80 for Christmas—an early and formative lesson in the power of automation to improve productivity. That instinct carried through to my years as an investment banker, where I built tools to automate routine workflows whenever I found time.

Niamh is an AI Research Scientist based in Silicon Valley. As a researcher and early access partner, she helped launch multimodal foundation models from OpenAI and DeepMind and open LLMs from Meta-Llama and Mistral. Alongside, Niamh is a trusted advisor to governments, think-tanks and international agencies on emergent technologies.

Ophélie is an associate on the investment team in Europe. Prior to Intrepid, she worked at Morgan Stanley in London. She previously gained investing experience at World Fund, an early-stage venture fund in Munich, ENGIE’s corporate venture capital arm and a mid-cap private equity firm in Paris.

Richard Sutton pioneered one of the most powerful techniques of the modern AI revolution: Reinforcement Learning.

Sendhil is Professor of Economics and Peter de Florez Professor of EECS (Electrical Engineering & Computer Science) at MIT. His current research uses machine learning to understand complex problems in human behavior, social policy, and especially medicine, where computational techniques have the potential to uncover biomedical insights from large-scale health data. Sendhil is cofounder of Nightingale, the computational medicine initiative, Pique, an app that changes how people read books and learn, and Dandelion, a company that catalyzes AI in healthcare.

Air Chief Marshal Sir Mike Wigston was Chief of the Air Staff from 2019-2023, the 4-star commander and head of the Royal Air Force. As principal air and space advisor to the Prime Minister, Secretary of State for Defence, and the Chief of Defence Staff, he was one of the youngest ever to hold the role.

Stephen helps lead our sourcing and investing efforts in the UK and Europe. Prior to Intrepid, Stephen was an investor with SoftBank Vision Fund and Atomico in London, where he worked with companies including Perk, Grab, Pipedrive, Bird (fka MessageBird), and Rovio.

Talia is a clinician leader and executive advisor at the intersection of business and healthcare, with responsibility for the strategic and day-to-day success of major corporate engagements. She is Physician Lead of Advisory Services at Cleveland Clinic based in Canada, holding P&L responsibility and advising cross-industry executives. She is a member of the Senior Leadership Team which includes developing annual strategic and financial planning, succession planning, setting of corporate policy, talent management, risk management as well as monitoring of corporate performance against business plans and KPIs.

Ttisa is an associate on the investment team in North America. Prior to Intrepid, Ttisa was an associate at CPP Investments, where she worked in its Leveraged Finance group, executing high-yield credit investments in the software space. Before joining the Leveraged Finance group full-time, Ttisa spent time as a rotational analyst at CPP, rotating across Growth Equity, Leveraged Finance, and Infrastructure.

Jim Weiss advises Magnetic Ventures and is founder and chairman of Real Chemistry, which combines healthcare communications, data and technology. He began his corporate career at Genentech and has supported biopharma and digital health companies and research organizations.

Umut Eser is a Venture Partner at Magnetic Ventures, co-founder of Weave Bio and Head of Generative AI at Johnson & Johnson Innovative Medicines. He trained in applied physics at Stanford and computational biology at Harvard and previously held AI leadership roles at Quantum-Si, AI Therapeutics, Cellarity and Doctor Evidence.

Christine Aylward founded Magnetic Ventures in 2018 and leads it as Managing Partner. She formerly served as a managing director at Foresite Capital and worked across healthcare innovation at Roche, Sanofi and Genomic Health. Her work spans technology, diagnostics and biotechnology investing. She is also a board member of Relation Therapeutics, confirmed by its current directory and financing announcement. She is also a director of Amydis, confirmed by both companies' current directories.

Jillian Shaw is a Venture Partner at Magnetic Ventures, focused on AI-assisted drug discovery and precision genetic medicines. She is an Institute Scientist at the Broad Institute and co-leads its Ladders to Cures rare-disease accelerator. Her background includes synaptic physiology and neurodevelopmental disorders, with a PhD from USC and postdoctoral research at Stanford.

US venture capital firm founded by Christine Aylward in 2018, backing companies at the intersection of deep technology and life sciences. Magnetic Ventures invests in AI, machine learning, multiomics, drug discovery, precision medicine and technology-enabled healthcare, typically entering at seed or Series A with initial checks of $1–6 million. Its current offices are in Boston, Miami and Research Triangle Park. The team comprises a founder and managing partner, two venture partners and three advisers. Portfolio companies include Proxima Bio, Weave Bio, Relation Therapeutics, Deep Genomics, Transition Bio and Gilgamesh Pharmaceuticals. Magnetic Ventures Management, LLC reports Funds I and II; reported asset values and fundraising targets are distinct from completed fund closings. This US healthcare firm is separate from Berlin infrastructure investor Magnetic Capital.

Big Sur Ventures is a Madrid-based venture capital firm investing from pre-seed through Series A in technology companies. Operating since 2012, it backs scalable software and internet businesses alongside deep tech in quantum systems, AI, advanced materials, photonics, microelectronics and nanotechnology. It supports founders with operational advice, transaction experience and commercial networks, typically investing EUR100,000 to EUR1 million initially. Its regulated management company is Big Sur Ventures SGEIC SA, registered with the CNMV as number 142 in 2019. Its BSV IV Ariadne fund finances early-stage deep tech and digital technology companies.

Tolemy Bio develops an AI-based virtual cell platform for therapeutic development and manufacturing. It combines software, physics, systems biology and laboratory experimentation to help teams map, simulate and improve living cellular systems. Its work spans cell biology, advanced therapies and bioprocessing, using experimental data to support predictive modelling and better biological development decisions. The company operates from Cambridge in the UK and Barcelona in Spain.

Serena Yang serves as Senior Analyst, Portfolio Operations at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Stephanie Yan serves as Senior Associate at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Liz Wuestling serves as Vice President, Business Analytics & Strategy at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Monet Uva serves as Office Operations Manager at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Tim Schmidt serves as Vice President, Fund Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Katie Savage serves as Office Receptionist at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Elias Quijano serves as Principal at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Hyewon Park serves as Assistant Controller, Funds at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Sarah Queen serves as Assistant Controller, Corporate Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Wes Long serves as Senior Analyst at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Andrew Lee serves as Managing Director at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Anjali Jagannath serves as Vice President, Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ivan Learmont serves as Vice President, Information Technology & Facilities at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Maggie Kehoe serves as Senior Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ben Hartheimer serves as Senior Associate, Portfolio Operations at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Catherine Gamble serves as Manager, Corporate Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Nick Futrell serves as Senior Associate at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Alexis Fleming serves as Manager, Portfolio Operations & Administration at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Daniella Doolen serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ashley Cowher serves as Senior Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Madison Bedwell serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Lydia Allison serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Andrea Jackson serves as Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Pat Smerkers serves as Chief Financial Officer, Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Sharon Kedar serves as Co-Founder, Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Michael P. Rubin serves as Founder & CEO at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

BioAdvance Capital is an evergreen life sciences investor that provides early-stage capital and company-building support to businesses improving human health in the US Mid-Atlantic region. It focuses on seed and Series A companies headquartered along the New York-to-Washington corridor, investing in therapeutics, medical devices, digital health, diagnostics and research tools. Its initial investments typically range from USD500,000 to USD1.5 million, with capacity to invest up to USD5 million over a company’s development. Its portfolio includes neurological drug development, brain-injury assessment, cell and gene therapies and AI-enabled healthcare and drug discovery. Returns from portfolio exits support further investments through its evergreen model.

InfraScan develops and commercialises handheld near-infrared devices that screen head-injury patients for intracranial bleeding. Its Infrascanner compares light absorption on opposite sides of the head to identify suspected hematomas and help clinicians prioritise CT referral and neurosurgical assessment. The portable system is used in emergency care, intensive care, military and other settings where rapid brain-injury triage is needed. It is a screening tool with defined detection limits, rather than a replacement for diagnostic CT imaging.

Physician and healthcare innovation leader, formerly global head of healthcare for venture capital and startups at Amazon Web Services and chief innovation officer at Virtua Health.

Medical technology executive with previous leadership roles at CardioNet, Viasys Healthcare and Respironics.

Biomedical engineering scientist at Drexel University specialising in signals, systems and biomedical signal processing.

Life science company builder who led BioAdvance as chief executive from 2002 to 2021, with previous biotechnology executive and legal experience.

Physicist and medical device executive with electro-optics, ophthalmic imaging and medical laser commercialisation experience.

Medical technology commercial leader with previous sales leadership roles at Z-Medica and Olympus America.

Electrical engineer experienced in medical device development, manufacturing and communications equipment, formerly at Valley Forge Scientific.

Physician and engineer experienced in life science investment management, therapeutics strategy and software for drug development.

Founding partner of Purposeful Advisors and former global communications leader at NASDAQ, with experience in corporate reputation and strategic communications.

Provides operational and executive administration support, with previous medical device and pharmaceutical business experience.

Physician and biomedical executive experienced in pharmaceutical, biologic and cell therapy development at IVAX, Centocor and Johnson & Johnson.

Pulmonologist and clinical development executive experienced in research, regulatory strategy and biopharmaceutical development.

Deputy secretary for technology and entrepreneurship at Pennsylvania’s Department of Community and Economic Development, as identified in BioAdvance’s board directory.

Physician-scientist and dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania Health System, as identified in BioAdvance’s board directory.

Entrepreneur in medical device distribution and pharmaceutical development in Taiwan and China, including Progressive Group and Sino Pharma.

Former managing director of alternative investments at the Pennsylvania State Employees’ Retirement System.

Physician experienced in pharmaceutical business development, strategic partnerships and venture investing; former Novartis strategic partnerships executive and BioAdvance venture partner.

Manages BioAdvance’s applicant outreach, funding review process and research into regional growth and portfolio development.

Drug discovery and development scientist with experience at Trevena, Centocor, GlaxoSmithKline and Merck and an investment committee role at BioAdvance.

Medical technology licensing and robotics entrepreneur with experience at Non-Invasive Technology and U.S. Robots.

President emeritus and Linwood F. Tice Professor emeritus at the University of the Sciences.

Frederick “Rick” Jones is a physician, executive and life science investor experienced in therapeutics and devices, including at Broadview Ventures and Anchor Therapeutics.

Life science finance professional experienced in reporting, budgeting, treasury and internal controls, including at BioRexis and Targeted Genetics.

Venture capital professional identified by BioAdvance as a partner at First Round Capital.

Life science investor and entrepreneur experienced in medical devices, diagnostics, research tools and digital health; formerly led Kodak’s life science division and Zargis Medical.

Physician and biotechnology executive, chairman and chief executive of Cabaletta Bio and adjunct professor at the Wharton School, as identified in BioAdvance’s board directory.

International sales and distribution executive with previous experience at Kodak Graphic Arts.

Kathy Yi joined Transition Bio's board in 2022. She formerly served as COO of Affini-T Therapeutics and CFO of Cerevel and Sangamo Therapeutics, with earlier finance roles at Novartis and Life Technologies. She holds a chemical engineering degree from UC Berkeley and an MBA from Columbia.

Robert Weeks joined Transition Bio's board in 2024. He advises a private charitable foundation on its endowment and operations and previously served as chief of staff to TD Ameritrade's board chairman. He studied economics and finance at Washington University in St. Louis.

Diana Bernstein joined Transition Bio's board in 2026 and is a Director at Northpond Ventures focused on biotherapeutics. She previously worked at MRL Ventures Fund and Flagship Pioneering and holds a pharmacology PhD from the University of Pennsylvania. Northpond’s current team lists Diana Bernstein as Director.

Gregory M. Bokar joined Transition Bio's board in 2026. He is Managing Director of UVB Capital Management, with experience in company formation, licensing, acquisitions and corporate governance. His earlier legal leadership roles included Flagship Pioneering, Sumitomo Pharma America Holdings, Sunovion and Elan.

Shilpi Arora is President and Chief Scientific Officer of Transition Bio. She previously led discovery and translational biology at Exo Therapeutics. Her experience spans target validation, pharmacology and translational research in oncology, inflammation and rare disease, following cancer biology training at the All India Institute of Medical Sciences.

Sarah Teichmann is a scientific co-founder of Transition Bio. A Cambridge stem cell medicine professor and former head of cellular genetics at the Wellcome Sanger Institute, she co-founded and co-leads the Human Cell Atlas initiative.

Peter St George-Hyslop is a scientific co-founder of Transition Bio and a Columbia University neurology professor. His research identifies genetic and molecular causes of neurodegeneration, including Alzheimer's disease.

Cambridge, Massachusetts and Cambridge, UK biotechnology company combining microfluidics, biophysics and machine learning to discover small molecules targeting biomolecular condensates and intrinsically disordered proteins. Its Condensomics platform generates experimental data for AI-guided target discovery and compound optimization. Programs include MYC-driven cancers and neurodegeneration; a Voyager Therapeutics collaboration targets TDP-43 pathology in ALS and frontotemporal dementia. Current research includes YTHDC1 inhibitors and Ewing sarcoma target EWS-FLI1, without evidence of an approved medicine. Launched in 2020 with seed backing led by Lifeforce Capital, Transition Bio raised a $50 million Series A in 2022 led by Northpond Ventures and received a $750,000 Little Warrior Foundation research grant in September 2026. Potential Voyager milestones are commercial terms, distinct from venture financing.

Criteria Bio Ventures is the evergreen life sciences investment platform of CriteriaCaixa, managed through Caixa Capital Risc (also branded Criteria Capital Risc). It invests in private biotechnology companies developing therapies and healthcare technologies, from early development to growth stages. It concentrates on Spain, Portugal and the rest of Europe and selectively invests in North America, providing patient capital, scientific expertise and strategic support across therapeutic modalities and disease areas. Its portfolio includes treatments for neurological and rare diseases, immunotherapies, gene therapies and medical technologies. Criteria Bio Ventures SICC SA is a distinct investment vehicle registered with the CNMV in 2021; its regulated manager is Caixa Capital Risc SGEIC SA.

Tolerance Bio is a biotechnology company developing therapies that restore, preserve or modulate the thymus, the organ that trains immune T cells, to treat immune-mediated disease. Its research combines off-the-shelf induced pluripotent stem cell-derived thymic tissue with pharmacological and biologic approaches to immune tolerance and regeneration. Potential applications include autoimmunity, transplantation, cancer, infections, immune deficiencies and allergy. In 2026 it licensed the clinical-stage IL-7 fusion protein efineptakin alfa and anti-IL-33 antibody TLB-33 (formerly MT-2990) to expand its thymus-focused development pipeline. TLB-33 Phase 2 studies are planned for 2027. These are investigational programmes, with efficacy in the company’s proposed indications still under development.

University of Miami cellular transplantation scientist, inventor of pancreatic islet isolation technology and director emeritus of the Diabetes Research Institute.

Cell therapy bioanalytical scientist experienced in stem-cell-derived NK cell assays and GMP quality control at HebeCell, with doctoral research into microglia and neurodegeneration.

Biologics and cell and gene therapy programme manager experienced in CMC strategy and cross-functional development at Beam Therapeutics and Regeneron.

Stem-cell scientist at the University of Florida researching functional human thymic tissue and pancreatic islets derived from pluripotent stem cells.

Immunologist experienced in research, medical affairs and scientific communications at JDRF, Provention Bio, Sanofi and Orna Therapeutics.

Dana-Farber immunology and cellular therapy researcher studying immune recovery after stem cell transplantation and cancer immunotherapy; formerly executive director of its Cell Manipulation Core Facility through June 2024.

Certified public accountant experienced in financing, accounting and financial operations for biotechnology companies including Provention Bio and Iveric Bio.

Biotechnology regulatory affairs and research executive with previous leadership roles at Sanofi and Provention Bio, including development of type 1 diabetes immunotherapies.

Physician and clinical development executive experienced in diabetes, stem cell therapies and medical devices, formerly chief medical officer at ViaCyte and named chief medical officer of Aardvark Therapeutics in Tolerance Bio’s published biography.

Columbia University immunologist researching transplantation, tolerance induction, xenotransplantation and type 1 diabetes.

Preclinical and clinical immunology and pharmacology leader experienced in biomarkers and therapeutic development at Roche, Janssen and Provention Bio/Sanofi.

Biopharmaceutical business development and alliance management executive previously at Provention Bio, Allergan, Actavis, Watson Pharmaceuticals and Eden Biodesign.

Biologics and respiratory drug discovery scientist, chief scientific officer of Spirovant and former respiratory, inflammation and autoimmune research leader at MedImmune/AstraZeneca.

Cell and gene therapy manufacturing scientist with experience at Beam Therapeutics and Semma Therapeutics and a background in mechanobiology and nanomaterials.

Al Kelly is a board member of Ride Therapeutics and an advisory director at Berkshire Partners. He formerly led Visa as CEO and chairman and held executive roles at American Express. He earned undergraduate and MBA degrees at Iona University.

Thomas Hughes, listed as Tom Hughes by Ride Therapeutics, serves on its board. He previously led Deutsche Asset Management and held senior trading and financing roles at Merrill Lynch. He co-founded Fieldpoint Private Bank & Trust and studied naval architecture and marine engineering at the United States Merchant Marine Academy.

David Weitz is a scientific co-founder of Ride Therapeutics. A Harvard professor and Wyss Institute faculty member, he studies soft matter, biophysics and biomaterials and has helped establish multiple technology companies. He is also a scientific co-founder of Transition Bio.

Tuomas Knowles is a scientific co-founder and board member of Ride Therapeutics. A Cambridge physical chemistry professor, he researches protein aggregation, self-assembly and microfluidic methods. His other spinouts include Transition Bio, WaveBreak Therapeutics and Xampla. He is also CTO, scientific co-founder and executive director of Transition Bio.

Emer Reynolds leads alliances and corporate strategy at Ride Therapeutics. She previously held senior roles at Elan, Malin, Wren Therapeutics and Radius Health, working across partnerships, business development, investor relations and corporate affairs. She is a University College Dublin graduate.

George Kelly Martin, also known as G. Kelly Martin, is chairman and co-founder of Ride Therapeutics. He also co-founded Transition Bio. His previous leadership roles include CEO of Elan, Malin, Novan and Radius Health and senior positions at Merrill Lynch. He studied politics at Princeton. He is also executive chairman and co-founder of Transition Bio.

Samuel Cohen is CEO and co-founder of Ride Therapeutics and serves on its board. He previously co-founded and led Wren Therapeutics and helped found Transition Bio. His background includes biotechnology investing at Malin, strategy consulting at BCG and biophysical chemistry research at Cambridge. He is also an executive director and co-founder of Transition Bio.

Timothy Welsh leads platform technology at Ride Therapeutics, which he co-founded. He previously helped build technology platforms at Transition Bio and Flagship Pioneering and earned a doctorate in biophysical chemistry at Cambridge.

Cambridge biotechnology company developing AI-designed, non-viral delivery carriers for genetic medicines. Its Molecular Logistics platform combines high-throughput nanoparticle engineering and in-vivo screening with a generative model trained on biodistribution measurements. The company reports delivery hits across multiple tissues, including brain and lung; its cystic fibrosis delivery program remains preclinical. Ride emerged from Harvard and Cambridge research, with a UK entity incorporated in 2022 and a public launch in 2023 backed by $8 million in seed funding. In September 2026 the Cystic Fibrosis Foundation announced a commitment of up to $7.3 million for lung delivery development. That conditional commitment is distinct from seed cash already raised.

Anecon Inversiones is an independent Andalusian family office based in Seville that invests its own capital and co-invests with strategic partners in private companies and real assets across Iberia. It uses equity and debt structures to support growing businesses, infrastructure and real estate, with active involvement and a long-term approach to preserving and creating value. Its investments span technology, agriculture and food, and it entered biotechnology through an investment in neurodegenerative drug developer ONESTX.

Clinical and basic immunologist and biotechnology entrepreneur who founded Tolerance Bio and co-founded Provention Bio, Celimmune and Glutenostics. He is also a personal investor in ONESTX. His career includes immunology research and drug development at NIH, BMS, MedImmune and Janssen.

David A. Mount serves as treasurer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Dodzie Sogah serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric C. Schneider serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric J. Sorscher serves as nonvoting medical advisory council chair at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eric R. Olson serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Jennifer L. Taylor serves as nonvoting cf adult care center representative at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

John S. Weinberg serves as executive vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Kate O'Donnell serves as national volunteer leadership council chair at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Paul A. Motenko serves as nonvoting advisor at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Peter J. Mogayzel Jr. serves as nonvoting pediatric cf care center representative at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Robert H. Niehaus serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Steven Shak serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Adela Skenderasi serves as chief investment officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Albert Faro serves as senior vice president and chief medical officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Carole B. Griego serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Catherine C. McLoud serves as nonvoting chair emeritus at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

D. Paul Flessner serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Dominic J. Caruso serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Eleana Seek serves as senior vice president and chief audit and risk officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Elise Eberwein serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Heather Culp is senior vice president and chief development officer of the Cystic Fibrosis Foundation, joining on August 10, 2026 to lead fundraising and donor engagement. Previously she led philanthropy at University of Maryland Medicine and fundraising for Johns Hopkins neurology and brain sciences. She trained in English at Washington College and law at the University of Maryland and practiced law before moving into philanthropy.

James (Jamie) R. Butler, II serves as nonvoting advisor at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Jessica H. Boyd serves as trustee at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

KC Bryan White chairs the Cystic Fibrosis Foundation’s board of trustees. She joined the board in 2005 and became chair in 2022. A founding member and former chair of the Foundation’s Adult Advisory Council, she helped establish BreatheCon and created the ROSE UP fundraising event.

Louis A. DeFalco serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Marin Goings serves as senior vice president and chief of strategy at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Mary B. Dwight serves as senior vice president and chief policy and advocacy officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Molly Riley serves as senior vice president of field management at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Steven Rowe serves as executive vice president and chief scientific officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Sue Sullivan serves as vice president of community partnerships at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Teresa L. Elder serves as vice chair of the board of trustees at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Timothy A. Waire, Jr. serves as senior vice president and chief information officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Yvonne Massenburg serves as senior vice president and chief people officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Bethesda, Maryland nonprofit funding cystic fibrosis research, drug development, specialized care and patient advocacy. Founded in 1955, it uses venture philanthropy through its CF Foundation Mission Ventures investment arm to fund biotechnology companies across development stages. Its focus includes genetic medicines, lung-targeted nucleic acid delivery, infection treatments, diagnostics and other cystic fibrosis complications. Funding may involve equity, research agreements, milestone payments or royalties; financial returns support the Foundation’s mission. Its current published portfolio includes 24 companies, including Gensaic, Nanite, ViaNautis, Prime Medicine, ReCode Therapeutics and AI-based delivery developer Ride Therapeutics. Michael P. Boyle is president and CEO and KC Bryan White chairs the board. The Foundation’s research budgets and philanthropic fundraising campaigns are distinct from externally raised venture funds.

Irena Barisic serves as executive vice president and chief operating and financial officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

JP Clancy serves as senior vice president of clinical research at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Kathryn Brown serves as senior vice president and chief communications and marketing officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Michael Cavadel serves as senior vice president and chief legal officer at the Cystic Fibrosis Foundation, a nonprofit supporting cystic fibrosis research, therapeutic development, care and patient advocacy.

Michael P. Boyle is president and chief executive officer of the Cystic Fibrosis Foundation and a member of its board of trustees. A physician and cystic fibrosis clinical researcher, he previously led the Foundation’s therapeutics development from 2015 to 2019. He trained at Johns Hopkins, founded its Adult CF Program and remains an adjunct professor who sees patients there.

Alia Mentis develops proprietary advanced composite materials, manufacturing processes and integrated production technologies. It combines material research, industrial design, prototyping, pre-series manufacturing and validation in-house for aerospace, automotive, motorsport and protective equipment customers. Its proprietary technologies include Koridion and Xelion. The company is based in Montebelluna, Italy, and listed on Euronext Growth Milan in June 2026.

Axon Partners Group Investment, SGEIC, SA is the CNMV-regulated Spanish private-market fund manager within Axon Partners Group. It manages vehicles that invest directly in growing technology businesses and climate transition companies, regional innovation investments in Andalucía, and funds of venture capital funds. Its mandates include Axon Innovation Growth II, its companion Growth Investment vehicle, EU-LATAM Climate Transition II and Axon Desarrollo Andalucía. The management company is legally distinct from the listed investment and consulting parent group.

Axon group managing partner and a director of its regulated Spanish fund management subsidiary. Official CNMV records verify the full legal name and management-company board role.

Consulting partner at Axon, promoted after more than twelve years with the firm. The firm’s own announcement identifies his full name as Carlos Gómez Herrero.

Axon group managing partner and a director of its regulated Spanish fund management subsidiary. Official CNMV records verify the full legal name and management-company board role.

Nathan Higginson-Scott was appointed chief research and development officer of Gensaic in January 2026 to lead scientific strategy and therapeutic development. He previously served as chief technology officer and senior vice president of drug creation at Seismic Therapeutic and as vice president of biotherapeutics at Pandion Therapeutics. Earlier, he worked at Pfizer. He earned a doctorate in molecular immunology and a master’s degree from Imperial College London and a microbiology degree from the University of Kent.

Jill Milne joined Gensaic’s board in June 2026. She co-founded Catabasis Pharmaceuticals and previously served as its CEO and as president and CEO of Astria Therapeutics. She brings scientific, operational and public-company leadership experience to Gensaic’s cardiometabolic and RNAi programs.

Karina Thorn is a board observer at Gensaic and a Novo Nordisk nucleic acid research leader. She has a PhD in biochemistry from the University of Copenhagen and joined Novo Nordisk in 2014, following several years working in Boston.

Liang Schweizer joined Gensaic’s board in May 2026. She is founder and CEO of DISruptive Oncology and previously served as chair and CEO of HiFiBiO Therapeutics. Gensaic identifies her experience in scientific leadership and global biotechnology company building.

Neil Exter joined Gensaic’s board in May 2026. A retired partner of Third Rock Ventures, which he joined in 2007, he has more than 30 years of biotechnology and technology operating, business development and strategy experience. He earned engineering degrees from Cornell and Stanford and an MBA from Harvard.

Gabrielle Mitchell-Lee is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Sungmin Baek is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Emanuel Burgos is computational biologist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Neo Ruiz is research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Evans Wralstad is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Jonathan Sands is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Alex Wang is senior scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Maggie Lejeune is associate scientist at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Maya Orzach is senior research associate at Gensaic, a biotechnology company developing AI-designed tissue-selective delivery systems and multifunctional RNA therapeutics.

Jonathan Hsu is chief technology officer and co-founder of Gensaic. An MIT PhD alumnus from 2022, he founded the company with Lavi Erisson and Uyanga Tsedev in 2021. Gensaic combines protein engineering and machine learning to develop tissue-selective delivery systems.

Lavi Erisson is CEO, co-founder and a board member of Gensaic. A physician and MIT Sloan MBA alumnus, he previously worked in drug development at Teva and as chief medical and business officer of Iterative Health. He founded Gensaic with Uyanga Tsedev and Jonathan Hsu in 2021.

Uyanga Tsedev is chief scientific officer and co-founder of Gensaic. She earned her MIT master’s degree in 2015 and doctorate in 2021, researching engineered phages in Angela Belcher’s laboratory. She is principal investigator on Gensaic’s NIH-supported phage-derived gene delivery project for muscle diseases.

Cambridge, Massachusetts biotechnology company founded by Lavi Erisson, Uyanga Tsedev and Jonathan Hsu in 2021 as an MIT spinout, formerly M13 Therapeutics. Its FORGE Engine combines protein language models, sequence-to-function experiments and AI-assisted gene-pair discovery to design tissue-selective delivery ligands and multifunctional siRNA conjugates. Current programs target obesity with lean-mass preservation, obesity with MASH, and cardiometabolic disease, all in preclinical discovery or lead optimization. Earlier phage-derived gene delivery work included rare CNS targets with Ovid Therapeutics and CFTR delivery with the Cystic Fibrosis Foundation. Ovid invested through equity and a convertible note; its CNS collaboration was amended in January 2026. Gensaic also has a tissue-targeting discovery collaboration with Novo Nordisk and an NIH muscle gene delivery grant. Potential commercial milestones and conditional foundation commitments are distinct from completed equity financing.

Eholo develops subscription software for psychologists and mental health clinics to manage appointments, patient records, informed consent, billing, payments, reminders and video consultations. Its integrated AI tools transcribe sessions and help prepare clinical summaries for professional review, reducing administrative work for practitioners. Co-founders Sonia Torras Garat, a health psychologist, and Eduard Martí Vaquer, an engineer and programmer, created the business during the COVID-19 pandemic.

ONESTX (Olavide Neuron STX SL) is a Spanish biotechnology spin-off of Universidad Pablo de Olavide developing investigational drugs for neurodegenerative diseases. Its lead candidate LON-21 (STX64/irosustat) is an oral steroid sulfatase inhibitor designed to alter sulfated neurosteroid levels and restore protective signalling in the brain. Its development programme focuses on Huntington’s disease, with broader research into Alzheimer’s, Parkinson’s and age-related cognitive disorders. In March 2026 the company announced FDA orphan drug designation for Huntington’s and plans for a multicentre Phase IIa proof-of-concept trial, supported by a Series A financing still being finalised. The therapeutic benefits reported to date in these conditions are preclinical.

Pharmacist and biotechnology entrepreneur experienced in diagnostics, research management and technology transfer; also a founder and chief executive of Biomedal.

Universidad Pablo de Olavide professor researching cognition, nociception, aging and steroid sulfatase inhibitors in neurodegenerative disease.

Neuroscience and pharmacology researcher with previous senior preclinical development roles at WeLab Barcelona and ESTEVE.

Engineer, programmer and co-founder of Eholo’s psychology practice management platform.

Distinguished researcher at Universitat Jaume I experienced in biomedical research management and technology transfer.

Pharmacologist and biotechnology executive experienced in endocrine therapies and steroid sulfatase inhibitors, including roles at Oxandia, Gliagenesis and Estryx Pharma.

CSIC senior researcher at the Severo Ochoa Center for Molecular Biology studying the molecular mechanisms of neurological disorders.

Genetics and longevity researcher and professor at Universidad Pablo de Olavide, developing the steroid-sulfatase research underpinning ONESTX.

Neurologist specialising in Alzheimer’s disease and co-founder and medical director of Fundación ACE.

Aging biology researcher studying steroid sulfatase inhibition and neurodegeneration in animal models; co-inventor of patents underpinning ONESTX.

Biotechnology strategy and business development adviser with previous leadership roles at Digna Biotech and OWL Metabolomics and pharmaceutical experience at Boehringer Ingelheim.

Molecular biologist and research project manager experienced in biotechnology development and technology transfer into clinical development.

Health psychologist and co-founder of Eholo, developing tools to simplify the daily administration of psychology practices.

Neurologist and clinical group coordinator at Fundación CIEN, experienced in dementia research and clinical trial design.

Neuroscientist experienced in preclinical and clinical development, biomarkers and neuroimaging, with previous roles at Noscira, Syneos Health and Peaches Biotech.

Eoniq Venture Capital SL operates a Spanish pre-seed and seed investment platform that backs founders building technology-enabled businesses across AI, industrial technology, healthcare, software, climate, education, logistics and commerce. It sources companies throughout Spain, including regions outside Madrid and Barcelona, and supports portfolio growth and follow-on financing. Its first fund uses Gesalcalá as the regulated manager; Mediterranean Seed Fund II uses Mar Océana.

Fibtray develops patented food packaging made from natural cellulose fibre, intended to replace multilayer plastic trays. Its products support modified-atmosphere packaging and existing sealing lines, with formats for fresh food and prepared meals. The company manufactures in Europe and offers licensing of its packaging technology to other tray producers.

InspectRail develops onboard monitoring systems and software for preventive maintenance of railway infrastructure. Its sensors collect frequent measurements of track geometry and wear, overhead contact lines, wireless communications and surrounding infrastructure; its software helps operators visualise changes and identify maintenance needs. The company was launched as a Ceit spin-off in San Sebastián in November 2023.

Mar Océana Venture Capital Investments, SGEIC, SA is a regulated Spanish private-market investment manager based in El Puerto de Santa María, Cádiz. It manages investment vehicles for technology businesses, agricultural and food technology, and company growth. It is the corporate administrator and regulated manager for Eoniq Mediterranean Seed Fund II, which backs Spanish pre-seed and seed technology companies through Eoniq’s investment platform.

Eoniq investment professional, former nanophysicist and CFA charterholder, with experience evaluating private companies and investment portfolios in southern Europe.

Eoniq general partner experienced in public and private investment programmes and entrepreneurial ecosystems in Spain, particularly Andalucía.

External investment adviser to the Mar Océana board associated with Eoniq Mediterranean Seed Fund II, contributing expertise in artificial intelligence engineering and research strategy.

Entrepreneur and venture investor leading Eoniq Fund. The official incorporation notice for Fund II identifies him as Thomas Caspar Nigel Horsey and as the individual representative of its corporate administrator Mar Océana.

Supports Eoniq portfolio companies with commercial development, customer acquisition and scaling, and manages deal flow.

Scientific and clinical adviser to Ovid Therapeutics and neurosurgeon at the University of Chicago Medicine, where he directs neurovascular surgery and researches cerebral cavernous malformations. Ovid’s directory misspells his first name as Isam and incorrectly places Imad Najm’s biography beneath it; his identity and research are corroborated by University of Chicago sources.

Adviser to Ovid Therapeutics following his transition from chief financial officer in July 2026, when Charles Carter succeeded him. Ovid’s announcement states he will remain an adviser through the end of 2027; he is not its current CFO.

Neuroscientist and co-founder of Ovid Therapeutics, established with Jeremy Levin in April 2014. Previously served as Ovid’s president and chief scientific officer; its 2019 proxy describes his planned retirement from the board. This is a historical founding affiliation, not a current executive appointment.

Scientific and clinical adviser to Ovid Therapeutics and neurogenetics researcher at Baylor College of Medicine. Directs the Blue Bird Circle Developmental Neurogenetics Laboratory and studies genetic regulation of neuronal excitability, including epilepsy associated with Alzheimer’s disease and glioblastoma.

Scientific and clinical adviser to Ovid Therapeutics. An epilepsy specialist at Cleveland Clinic, where he directs the Epilepsy Center and studies epileptogenesis, focal cortical dysplasia and epilepsy surgery. Ovid’s site places his detailed biography beneath the separate Issam Awad heading; that misplaced biography is not attributed to Awad.

Scientific and clinical adviser to Ovid Therapeutics and neuroscience professor at Tufts University School of Medicine. Her research examines epilepsy, mood disorders, GABAergic inhibition and neurosteroids. Holds a neuroscience PhD from George Washington University.

Scientific and clinical adviser to Ovid Therapeutics and emeritus chief of pediatric neurology at UCLA Health. A clinician and researcher focused on epilepsy and child neurology, with an MD from Tulane and a PhD in medicinal chemistry from Washington.

Director of Ovid Therapeutics. A biotechnology founder and former investment banker who co-founded Exelixis, Epikast, Anadys Pharmaceuticals and Cellzome. His prior roles include chairing Biogen and investment banking leadership at Cowen and PaineWebber.

Director of Ovid Therapeutics and RNA interference drug discovery scientist associated with Alnylam Pharmaceuticals. Joined Alnylam in 2005 after Bristol Myers Squibb and contributed to development of siRNA delivery approaches. Distinct from Kevin FitzGerald, the Epsilogen executive already recorded in Adex.

Lead independent director of Ovid Therapeutics and chair of its Nominating and Corporate Governance Committee. A corporate governance lawyer with a long career at Cahill Gordon & Reindel and earlier service at the SEC. Holds a JD from Harvard Law School.

Director of Ovid Therapeutics and chair of its Science and Technology Committee. A physician-scientist and biotechnology entrepreneur with faculty roles at Harvard and the Broad Institute. Founded biotechnology companies and leads research that includes applying machine learning to therapeutic target discovery; this personal research does not establish an Ovid AI drug platform.

Director of Ovid Therapeutics and chair of its Audit Committee. Previously served as chief financial officer and treasurer at Intercept Pharmaceuticals and as chief executive officer and CFO at DOV Pharmaceutical. Holds an MBA from Wharton.

Co-founder and executive chairman of Ovid Therapeutics. Served as CEO before transitioning to executive chairman on January 1, 2026. Previously led Teva and strategic alliances at Novartis, and held executive leadership at Bristol Myers Squibb. Also chairs Gensaic’s board according to Ovid’s June 2026 quarterly filing. Distinct from Bessemer investor Jeremy Levine. He is also chairman of Gensaic’s board, as confirmed by Gensaic’s current directory and Ovid’s June 2026 filing.

Senior vice president of clinical development at Ovid Therapeutics, responsible for clinical strategy and medical affairs. Joined in 2020 after clinical development leadership at Marinus Pharmaceuticals, with experience in rare and general epilepsies. Holds a doctorate in physiology and biophysics from NYU and a psychology degree from Cornell.

Chief business officer of Ovid Therapeutics, joining in July 2026. His prior roles include business development leadership at Soleno Therapeutics, chief operating officer of Codexis, and business and commercial leadership at Sierra Oncology. Holds an MBA from UC Berkeley and an MS in biochemistry and molecular biology from UCLA.

Chief scientific officer of Ovid Therapeutics, responsible for non-clinical science, research and academic collaborations. Previously held R&D leadership at Generation Bio, Wave Life Sciences, Vertex and GSK’s neuroscience group. Holds a doctorate from Rockefeller University.

Chief medical officer of Ovid Therapeutics. Previously served as chief medical officer of Vigil Neuroscience and Affinia Therapeutics, and held clinical development leadership at Novartis Gene Therapies and AveXis. Earlier led the NIH Office of Rare Diseases Research. A neurologist with an MD from Bonn and an MS in biostatistics from Columbia.

Chief financial officer of Ovid Therapeutics, promoted in July 2026 after joining in 2024 to lead finance and financial planning. Previously held CFO positions at CERo Therapeutics, iCAD and GI Dynamics, with earlier roles at Transkaryotic Therapies and Mercer Management Consulting.

President and chief executive officer of Ovid Therapeutics, appointed CEO effective January 1, 2026 after serving as president and chief operating officer. Joined Ovid in 2021 and led its operations and strategic transformation. Previously built a reputation and risk management business at Syneos Health.

Chief strategy officer of Ovid Therapeutics, known as Tori Fort. Joined in 2025 and leads enterprise strategy, investor relations and strategic initiatives. Previously led strategy and corporate affairs at Frontier Medicines and founded the biotechnology consultancy uncapped within WPP.

New York biotechnology company developing small molecule medicines for epilepsies and other brain disorders associated with neuronal hyperexcitability. Co-founded in April 2014 by neuroscientist Matthew During and physician Jeremy Levin, it listed on Nasdaq in 2017 under OVID. Its current pipeline includes OV329, a next-generation GABA-aminotransferase inhibitor, in Phase 2 studies, and OV4071, an oral KCC2 activator, in Phase 1, as reported in August 2026. Meg Alexander became CEO in January 2026, with Levin continuing as executive chairman. Ovid holds equity investments in Graviton Bioscience and Gensaic and received equity in a Perceptive-backed soticlestat company in exchange for rights. Its partnered OV888/GV101 program was paused in late 2024. No company AI discovery platform has been verified.

Creand Asset Management is the commercial brand of Gesalcalá, SGIIC, SAU, the Creand group’s Spanish investment manager. Based in Madrid, it manages investment funds, SICAVs and portfolios across equities, fixed income and alternative investments. Its private-market products include a fund of emerging U.S. technology venture funds and minority stakes in venture managers, advised by Blue Opal Capital, and an affordable rental housing fund advised by OM Live Real Estate using data and AI to assess projects.

Also published as Luis Buceta Casteleiro. Managing director of business and investments at Creand Asset Management in Spain, registered as a general manager of Gesalcalá. Joined the Creand group in 2016 and previously worked at Chase Manhattan Bank and BNP Paribas.

Leads investment solutions, advisory services and discretionary portfolio management at Creand Asset Management in Spain. Joined the firm in 2015 and began leading its Spanish fund advisory and management team in 2023.

Investment director at Creand Asset Management in Spain since 2023, leading analysis and management of equities, fixed income, alternative investments and ESG. Joined Creand in 2015, after working at Deloitte and FCS Asset Management.

Director of Graviton Bioscience and chemistry professor at Princeton University. Shared the 2021 Nobel Prize in Chemistry with Benjamin List and has advised pharmaceutical companies and founded biotechnology companies.

Director of Graviton Bioscience, founder and chief executive officer of Optima Asset Management, and vice-chairman of FFT Wealth Management. Launched Optima’s flagship fund in 1988; earlier career included Kidder Peabody and UBS PaineWebber.

Senior vice president and head of chemistry at Graviton Bioscience. Previously led chemistry research at Kadmon and helped establish its ROCK2 program; earlier research included Alzheimer’s disease at Wyeth and metabolic disorders at Merck. Holds a PhD in organic chemistry from the University of Illinois Urbana-Champaign.

Senior vice president of clinical and scientific strategy at Graviton Bioscience. An oncology physician and researcher with experience leading clinical trials and translational research; his published work includes AI-assisted drug repurposing research during COVID-19. This personal research history does not establish an AI platform at Graviton.

Chairman of Graviton Bioscience and managing partner and co-founder of Pontifax, a life science investment firm. His biotechnology board experience includes Keros Therapeutics, Kamari Pharma, Luris Therapeutics and Adcytherix, with earlier directorships at Kite Pharma and Prevail Therapeutics.

Senior vice president of translational medicine at Graviton Bioscience. Previously held translational medicine leadership at Equilibre and led immunology at Kadmon, where she contributed to development of belumosudil for chronic graft-versus-host disease. Holds a PhD in immunology from the Weizmann Institute.

Senior vice president, general counsel and head of compliance at Graviton Bioscience. His legal experience covers healthcare commercial transactions, regulation, intellectual property and risk management. Holds degrees from Harvard, Yale and NYU School of Law.

Senior vice president of business development and chief of staff at Graviton Bioscience. With the company since its inception, she oversees collaborations, financing and internal business operations. Previously worked in strategy at life science companies and investment management at Goldman Sachs.

Executive vice president responsible for research, preclinical development and CMC at Graviton Bioscience. Involved since the company’s inception; previously led preclinical research and CMC at Equilibre and small molecule retomer drug discovery at MeiraGTx. Holds a PhD in biochemistry with a neuroscience research background.

Chief medical officer and senior vice president at Graviton Bioscience. Previously led clinical research at Equilibre Biopharmaceuticals and held radiology faculty positions at Mount Sinai and NYU, with research in breast MRI and PET/MRI. Holds an MD from UCLA.

Founder and chief executive officer of Graviton Bioscience, a developer of ROCK2 inhibitors for neurological, immune and fibrotic disorders. Previously founded and led ImClone Systems and Kadmon, and founded MeiraGTx; his background includes academic biomedical research.

New York biotechnology company developing selective ROCK2 inhibitors and other therapeutics for central nervous system, autoimmune, fibrotic and metabolic disorders. Founded in 2020 by Samuel Waksal. Its GV101 program received FDA IND clearance for Friedreich’s ataxia in August 2026, with a Phase 2 study planned to begin enrollment in the first quarter of 2027. Its broader published pipeline includes progressive multiple sclerosis, ALS and Alzheimer’s disease alongside non-neurological indications. The earlier Ovid collaboration for OV888/GV101 in rare CNS disorders was paused by Ovid in late 2024, according to its 2025 annual report; the Graviton website’s older collaboration description does not establish an active Phase 2 trial. Backers include Enavate Sciences, Cormorant, Pontifax, Ovid and Sanofi. No company AI platform has been verified.

Blue Opal Capital is a New York investment manager that backs emerging venture capital funds, acquires stakes in fund managers and makes co-investments. Its fund-of-funds platform selects entrepreneurial venture managers, particularly in the United States, to gain exposure to early-stage technology companies. The firm also pursues private equity opportunities and operates with partners in New York, Miami and Abu Dhabi.

Blue Opal Capital partner with over twenty years of investment management experience. Previously helped build Abu Dhabi Investment Authority’s venture capital programme, focusing on venture capital fund investments and co-investments.

Co-founder of Blue Opal Capital and its chief compliance officer. Previously a managing director at BRG in New York and head of private equity valuation activities at Abu Dhabi Investment Authority.

Partner responsible for Blue Opal Capital’s venture investment activities. Previously co-founded PKRS.AI and worked on venture capital fund investments and co-investments in the private equity department of Abu Dhabi Investment Authority.

Chris Gagliardi serves as Director at Sudo Biosciences. Sanofi Ventures biotechnology investor and Sudo director. Previously worked in life sciences strategy consulting at L.E.K.; trained in chemistry.

Dan Estes serves as Director at Sudo Biosciences. Sudo co-founder and board director and Frazier Life Sciences general partner. Invests in and forms private biopharmaceutical companies; previously consulted with McKinsey and trained in biomedical engineering.

Dave Johnson serves as Director at Sudo Biosciences. Sudo board director and founder and CEO of Solve Therapeutics. Previously led VelosBio and Acerta Pharma and chaired Lengo Therapeutics.

Shinichiro Fuse serves as Director at Sudo Biosciences. Biotechnology investor at TPG Life Sciences Innovation with earlier investment and company-building experience at MPM Capital and business development at bluebird bio.

Gerry Thomas works in head of r&d project management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Terrie Walker-Smith works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Fenella Smith works in executive assistant at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Zainib Shabir works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Kejal Patel serves as Vice President, Clinical Operations at Sudo Biosciences. Clinical operations leader with earlier roles at Stargazer Pharmaceuticals, Outpost Medicine and Takeda, including global Phase 2b and Phase 3 trials.

Matt Nelan works in finance at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Peadar O’Donohoe serves as Vice President, Clinical Development at Sudo Biosciences. Clinical development physician with experience across neurology, sleep disorders, oncology and hematology; previously practiced anesthesiology and critical care.

Waylon Parham serves as Vice President, Finance & Controller at Sudo Biosciences. Finance executive and certified public accountant with previous controller and accounting leadership at Glympse Bio, Altavant Sciences and Syneos Health.

Kelly Munro works in clinical pharmacology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Cliona MacSweeney works in head of translational medicine at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Jack Kempster works in accountant at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Sarah Loughrey-Jennings works in clinical trial management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Anitha Jeyanthan works in r&d project management at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Roy Gray serves as Vice President, Non-Clinical Development at Sudo Biosciences. Nonclinical development leader who previously worked at Kadence Bio and GW Pharmaceuticals, including epilepsy drug development.

Sally Fillingham works in clinical trial administration at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Mark Evans works in neuropharmacology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Rachel Eccles serves as Vice President, Translational Pharmacology at Sudo Biosciences. Translational pharmacology scientist with previous project leadership at BenevolentAI and Pfizer and experience consulting on preclinical and IND-enabling development.

Vassilios Aslanis serves as Vice President, Clinical Pharmacology at Sudo Biosciences. Clinical pharmacology and pharmacometrics specialist with earlier leadership roles at Galecto, Ipsen, Novartis and Pierre Fabre.

Marsilio Adriani works in director, translational biology at Sudo Biosciences, a biotechnology company developing therapies for neurological and immune-mediated conditions. The company’s current staff directory documents this role.

Anjali Pandey serves as Senior Vice President, Medicinal Chemistry at Sudo Biosciences. Has led Sudo’s medicinal chemistry work since its 2020 founding. Previously worked at Lengo Therapeutics and in oncology companies affiliated with BridgeBio.

David Hennings serves as Senior Vice President, Chemistry, Manufacturing and Controls at Sudo Biosciences. Chemistry, manufacturing and controls specialist who previously worked on neurodegenerative drug development at Cortexyme and spent fourteen years at Array Biopharma.

Gordon McMurray serves as Chief Development Officer at Sudo Biosciences. Drug development scientist who co-founded Outpost Medicine and previously led research across neuroscience, pain and urology at Pfizer; earlier worked in pharmacology at Oxford.

Imran Babar serves as Chief Business & Financial Officer at Sudo Biosciences. Business and finance executive with prior roles at the orphan drug accelerator Cydan II and OrbiMed; co-founded Arvada Therapeutics and serves on the Rare Genomics Institute board.

Paul Bavier serves as Chief Legal Officer at Sudo Biosciences. Biotechnology lawyer with previous leadership roles at HilleVax, VelosBio, Avedro and Biodel. Holds a University of Michigan law degree.

Ian Mills serves as Chief Medical Officer at Sudo Biosciences. Physician and clinical development leader with previous roles at Outpost Medicine, Mitsubishi Tanabe and Pfizer; also an entrepreneur-in-residence with Frazier Life Sciences.

Biotechnology company based in Carmel, Indiana and London, developing selective small molecule TYK2 inhibitors for neurological and immune-mediated diseases. Its oral brain-penetrant SUDO-550 program targets multiple sclerosis and neuroinflammatory conditions; the company reported Phase 1 results in October 2025 and planned a Phase 2 study, whose initiation remains unverified. Its published pipeline also lists the topical dermatology candidate SUDO-286 in Phase 1 and an ophthalmic program in preclinical development. Founded in 2020 and backed by specialist life science investors.

Scott Byrd serves as Chief Executive Officer at Sudo Biosciences. Biopharmaceutical executive and Frazier Life Sciences entrepreneur-in-residence. Previously led Outpost Medicine, chaired Acacia Pharma, and oversaw commercialization at Cadence Pharmaceuticals.

Asahi Kasei Corp. is a Japanese diversified company whose businesses span materials, homes and healthcare. Its group develops chemicals, fibers, electronic materials, semiconductors, battery separators and membranes; builds and supplies housing and construction products; and develops pharmaceuticals, life-science technologies and medical devices. It conducts research, manufacturing and commercial operations through distinct operating companies in Japan and international markets. Its corporate venture capital activities invest in and develop partnerships with startups across healthcare, industrial technology, advanced materials and sustainability. The parent corporation is distinct from the Asahi Kasei Ventures investment program and from the Japanese pharmaceutical company Asahi Kasei Therapeutics Corp. The group traces its origins to 1922; the current parent corporation was established in May 1931.

Asahi Kasei Therapeutics Corp. is the Japanese pharmaceutical operating company of the Asahi Kasei group, formerly named Asahi Kasei Pharma Corporation. It researches, develops, manufactures and markets medicines, with work in orthopedics, critical and intensive care, immunology, urology and central nervous system diseases. Its pharmaceutical corporate venture capital program, established in 2018, invests in early therapeutic pipelines and drug-discovery platforms and supports potential collaborations with biotechnology companies, including Glycomine. The company was established in October 2003 and adopted its current name in April 2026. It is a distinct legal company from Asahi Kasei’s parent corporation and the pharmaceutical operations in the United States and Europe that adopted the shared Asahi Kasei Therapeutics brand in September 2026.